Valproate-Induced Hyperammonemic Encephalopathy in General Hospital Patients With One or More Psychiatric Disorders
Divalproex sodium/valproic acid (VPA) is an antiepileptic drug approved for use in epilepsy and bipolar disorder. Valproate-induced hyperammonemia occurs in up to 50% of VPA-treated patients, some of whom may become encephalopathic. Valproate-induced hyperammonemic encephalopathy (VHE) is thought to be rare, and for a variety of reasons, the diagnosis requires a high index of suspicion. (Source: Psychosomatics)
Source: Psychosomatics - February 23, 2017 Category: Psychiatry & Psychology Authors: Chandani Lewis, George E. Tesar, Roman Dale Tags: Original Research Reports Source Type: research
Valproate-induced Hyperammonemic Encephalopathy (VHE) in General Hospital Patients with one or more Psychiatric Disorders ☆
Divalproex sodium/valproic acid (VPA) is an antiepileptic drug approved for use in epilepsy and bipolar disorder. Valproate-induced hyperammonemia (VHA) occurs in up to 50 % of VPA-treated patients, some of which may become encephalopathic. Valproate-induced encephalopathy (VHE) is thought to be rare, and for a variety of reasons the diagnosis requires a high index of suspicion. The study ’s goals are to determine how common VHE is, and the quality of treatment provided when diagnosed. (Source: Psychosomatics)
Source: Psychosomatics - February 22, 2017 Category: Psychiatry & Psychology Authors: Chandani Lewis, George E. Tesar, Roman Dale Tags: Original Article Source Type: research
Using a graphical risk tool to examine willingness to take migraine prophylactic medications
Abstract: Many migraine sufferers use daily prophylactic therapy to reduce the frequency of their headache attacks. The Food and Drug Administration has approved several different medications for migraine prophylaxis, but it is not clear whether sufferers perceive these treatments to provide clinically significant benefits given their side effect profiles. Three hundred headache sufferers were recruited from the community and local headache clinics using print and television advertising. Participants reported experiencing problematic headache attacks with a median (IQR) frequency of 7.0 (4-13) headache days per month. Thes...
Source: Pain - September 27, 2016 Category: Anesthesiology Tags: Research Paper Source Type: research
Pharmacotherapy of conduct disorder: Challenges, options and future directions
There is a critical need for evaluation of the pharmacotherapies used in conduct disorder (CD), due to the high incidence of off-label prescribing. The aim of this review was to identify concerns associated with the safety, efficacy and impact on quality of life (QOL) that pharmacotherapy has in children and adolescents with CD. A systematic review was undertaken using pre-defined search criteria and four databases, including reference searches. We assessed these studies using the Strength of Recommendation Taxonomy, Grading of Recommendations Assessment, Development and Evaluation, and Review Manager Risk of Bias (RevMan&...
Source: Journal of Psychopharmacology - September 22, 2016 Category: Psychiatry Authors: Hambly, J. L., Khan, S., McDermott, B., Bor, W., Haywood, A. Tags: Reviews Source Type: research
Macrocytic isolated anaemia as an unusual adverse effect of divalproex sodium in the elderly
Publication date: Available online 10 August 2016 Source:European Geriatric Medicine Author(s): L. Godaert, L.A. Saint-Albin, L. Bousquet, J.-L. Fanon, M. Dramé (Source: European Geriatric Medicine)
Source: European Geriatric Medicine - August 10, 2016 Category: Geriatrics Source Type: research
Systematic Review and Meta-analysis of the Efficacy of Oral Medications Compared with Placebo Treatment in the Management of Postherpetic Neuralgia.
CONCLUSION: This review has provided favorable but low-quality evidence to support the use of anticonvulsants for PHN. Although statistically significant effects were observed for posttreatment pain and the percent of responders, the number of studies in each subgroup analysis for anticonvulsants was small and the included studies had high or unclear risk of bias. Further high-quality methodologic studies are needed to explore the effects of orally administered anticonvulsants for PHN.
PMID: 27472529 [PubMed - as supplied by publisher] (Source: Journal of Orofacial Pain)
Source: Journal of Orofacial Pain - July 30, 2016 Category: ENT & OMF Tags: J Oral Facial Pain Headache Source Type: research
Drugs for Bipolar Disorder
Date: August 15, 2016
Issue #:
1501Summary:
Bipolar disorder is characterized by intermittent
episodes of mania and/or depression. Even with
maintenance treatment, recurrences of manic or (more
frequently) depressive episodes are common. Some of
the drugs and dosages recommended here have not
been approved by the FDA for use in bipolar disorder. (Source: The Medical Letter)
Source: The Medical Letter - July 13, 2016 Category: Drugs & Pharmacology Authors: admin Tags: Abilify Antidepressants Antiepileptics Antipsychotics Aripiprazole Asenapine Bipolar disorder Carbamazepine Carbatrol Carbolith cariprazine Depakene Depakote Depression Divalproex sodium Electroconvulsive therapy Epival E Source Type: research
Remission of Psychosis in Treatment-resistant Schizophrenia Following a Seizure: A Case Report
Discussion
Improvement in our patient’s mental state was very drastic and very closely temporally associated with the occurrence of the seizure. Clozapine-induced seizures are known to occur, as clozapine decreases the seizure threshold, and the cumulative one-year risk of seizure is about five percent.[4] In our patient, the dose of clozapine was high and there was no other comorbid medical or neurological condition that could explain the seizure, leading us to the conclusion that the seizure was caused by clozapine.
ECT has been effective in improving patients on clozapine, and as ECT is based on the mechanism of seizu...
Source: Innovations in Clinical Neuroscience - June 1, 2016 Category: Neuroscience Authors: ICN Online Editor Tags: Case Report Current Issue ECT Epilepsy Neurology Psychiatry Schizophrenia clozapine electroconvulsive therapy (ECT) seizure Treatment-resistant schizophrenia (TRS) Source Type: research
WITHDRAWN: Anticonvulsant drugs for migraine prophylaxis.
CONCLUSIONS: Anticonvulsants appear to be both effective in reducing migraine frequency and reasonably well tolerated. There is noticeable variation among individual agents, but there are insufficient data to know whether this is due to chance or variation in true efficacy. Acetazolamide, clonazepam, lamotrigine and vigabatrin were not superior to placebo (one trial each). Relatively few robust trials are available for agents other than sodium valproate/divalproex sodium and topiramate; gabapentin in particular needs further evaluation. Trials designed with sufficient power to compare different drugs are also necessary.
...
Source: Cochrane Database of Systematic Reviews - May 26, 2016 Category: Journals (General) Authors: Chronicle EP, Mulleners WM Tags: Cochrane Database Syst Rev Source Type: research
Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder
Conclusions: These cross-sectional findings suggest it may be beneficial to monitor insulin sensitivity and body mass index in patients taking lithium or valproate in combination with a second-generation antipsychotic. (Source: Journal of Psychiatric Practice)
Source: Journal of Psychiatric Practice - May 1, 2016 Category: Psychiatry Tags: Articles Source Type: research
Release property study on the novel divalproex sodium enteric-coated capsules
Publication date: Available online 26 April 2016 Source:Saudi Pharmaceutical Journal Author(s): Shuoye Yang, Xin Wang, Jiangsong Jia, Pengyuan Li In present study, a novel divalproex sodium (DS) enteric-coated capsule was prepared, high performance liquid chromatography (HPLC) assay method for DS was developed. Their uniformity, release curve and release characteristics in different solvents were examined. The release studies were performed using marketed sample as a reference and data were analyzed in terms of cumulative release amounts as a function of time. It was demonstrated by the results that assay devel...
Source: Saudi Pharmaceutical Journal - April 26, 2016 Category: Drugs & Pharmacology Source Type: research
Cerebral Amyloid Angiopathy Presenting as New Onset Refractory Status Epilepticus(NORSE), Complicated by Psychosis, Dysautonomia and Posterior Reversible Encephalopathy Syndrome(PRES) (P6.219)
CONCLUSIONS: NORSE as the presenting symptom of CAA has been reported once but not in absence of CMB.There were other prominent psychotic features which als occurred prior to appearance of CMBs. Cortical hemorrhages appeared after, and probably as a consequence of PRES.The presentation and subsequent clinical course of this patient raised the concern for rapidly progressive dementia and a brain biopsy earlier in the clinical course might have helped in early diagnosis. We recommend that CAA should be considered strongly in differential for rapidly progressive dementia.Disclosure: Dr. Sharma has nothing to disclose. Dr. Sch...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Prasad, A., Sharma, S., Schmidt, E., Latorre, J. Tags: Behavioral and Cognitive Neurology: Clinical Syndromes Source Type: research
Safety and effectiveness of divalproex sodium extended release containing regimen in Indian patients with bipolar I disorder in continuation phase: Results of EASED registry.
Authors: Shah N, Reddy MS, Vohra S, Chaudhuri U, Mohanasundaram S
Abstract
The study was conducted to evaluate the safety and effectiveness of divalproex sodium XR containing regimen in patients with bipolar disorder (BPD) who are in continuation phase. It was an open-label, prospective, observational study conducted from July 2010 to December 2011 at 48 sites across India. Adult patients with bipolar I disorder of manic or mixed type fulfilling the DSM-IV criteria and who were in the continuation phase were included. Safety (primary outcome) was assessed by incidence of treatment emergent adverse events (...
Source: Asian Journal of Psychiatry - March 31, 2016 Category: Psychiatry Tags: Asian J Psychiatr Source Type: research
Divalproex sodium leading to sustained significant improvement in tardive dyskinesia in a patient with bipolar disorder.
Authors: Pattanayak RD, Charan D
PMID: 26985118 [PubMed] (Source: Indian Journal of Psychiatry)
Source: Indian Journal of Psychiatry - March 19, 2016 Category: Psychiatry Tags: Indian J Psychiatry Source Type: research
The rationale, design, and progress of two novel maintenance treatment studies in pediatric bipolarity.
DISCUSSION: Since the blind has not been broken on either of these clinical trials, conclusions about the maintenance effectiveness of either VPA or Li+ in youths with bipolar disorder type 1 or 2 cannot be made yet. Similarly, it is unclear whether VPA is superior to placebo in genetically high-risk youths with cyclotaxia. The final results of these trials should provide valuable information about the treatment of juvenile bipolar disorders.
PMID: 26975273 [PubMed] (Source: Acta Neuropsychiatrica)
Source: Acta Neuropsychiatrica - March 18, 2016 Category: Psychiatry Tags: Acta Neuropsychiatr Source Type: research
